Effects of compound from Chinese medicine on oxidation and anti-oxidation system of rat liver with steatohepatitis induced by high-fat diets
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 24
- DOI:
- 10.3969/j.issn.1009-3079.2005.24.007
- Key Word:
- 复方中药;氧应激;脂质过氧化;非乙醇性脂肪性肝炎
Abstract： 目的:探讨氧应激和脂质过氧化在高脂饮食所致脂肪性肝炎形成中的作用,复方中药防治非乙醇性脂肪性肝炎的作用机制.方法:雄性SD大鼠60只随机分组为6组,每组10只.正常组普通饲料喂养;模型I组、Ⅱ组喂高脂饲料;中药治疗I、Ⅱ组分别在喂饲高脂饲料9wk、13 wk予复方中药灌胃;饮食治疗组在喂饲高脂饲料13wk后改为普通饲料喂养.12 wk末处死正常组、模型I组、中药治疗I组大鼠;剩余3组大鼠继续喂养至16 wk末处死,测定血清转氨酶(ALT、AST),全血谷胱甘肽过氧化物酶(GSH-PX),肝匀浆丙二醛(MDA)含量,超氧化物歧化酶(SOD)活性,总抗氧化能力(T-AOC),一氧化氮(NO),诱导型一氧化氮合酶(iNOS),谷胱甘肽(GSH)水平,观察肝组织学改变.结果:模型组大鼠12 wk出现单纯性脂肪肝,16 wk发展为脂肪性肝炎.与正常组比,模型组大鼠肝组织脂质过氧化产物MDA含量明显增多(6.45±1.07,8.38±1.32μmol/g vs 5.08±0.91μmo1/g,P＜0.01),而抗氧化物SOD(171±14,148±26 kNU/gt vs 198±25kNU/gt,P＜0.05和P＜0.01),GSH(40.8±5.1, 35.0±9.0mg/g vs 48.5±7.6 mg/g,P＜0.05和P＜0.01),GSH-PX(11.2±1.5,10.3±1.8 μmol/L vs 16.4±3.7 μmol/L,P＜0.01)含量明显降低,且肝脏的脂肪变性严重程度随着高脂饮食喂养的时间延长而加剧.中药治疗组各项指标较模型组有明显改善(P＜0.05或P＜0.01),脂肪变性程度明显减轻.而饮食治疗组大鼠肝脏病理学仍呈轻-中度脂肪变性,各项指标与模型组比无显著差异.结论:氧应激和脂质过氧化在NASH形成中发挥重要作用,复方中药通过抗脂质过氧化等作用来治疗大鼠NASH.
- [1]曾民德.脂肪肝发病机制"二次打击"的假设[J].2001,(3).
- [2]海春旭.抗氧化剂、抗衰老与疾病控制的研究进展[J].2002,(4).
- [3]湛先保,李兆申,段义民,等.应激状态下胃碱分泌的变化及内源性NO作用初步研究[J].2002,(7).
- [4]Jun Fu Zhou,Dong Cai,Cheng Hong Peng,etc.A study on relationship of nitric oxide, oxidation, peroxidation, lipoperoxidation with chronic cholecystitis[J].2000,(4).
- [5]陈会松,柳利明,黄华,等.小鼠实验性肝损伤中NO的动态检测及意义[J].2003,(6).
- [6]Shi-Ping Ding,Ji-Cheng Li,CHANG Jin.A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide[J].2003,(3).
- [7]Hasegawa K,Taniai M,Ludwig J,etc.Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.[J].2002,37(1).
- [8]Walsh K,Alexander G.Alcoholic liver disease.[J].2000,76(895).
- [9]Day,CP,James,OF.Steatohepatitis: a tale of two "hits"? (editorial)[J].1998,114(4).
- [10]A E, Reid.Nonalcoholic steatohepatitis.[J].2001,121(3).
- [11]Younossi ZM,Ong JP.Approach to the diagnosis and treatment of nonalcoholic Fatty liver disease.[J].2005,9(4).
- [12]B, Nardo,P, Caraceni,P, Pasini,etc.Increased generation of reactive oxygen species in isolated rat fatty liver during postischemic reoxygenation.[J].2001,71.
- [13]Arun J, Sanyal.AGA technical review on nonalcoholic fatty liver disease.[J].2002,123(5).
- [14]Moreno Otero R,Medina J,Fernandez Salazar LI,etc.Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis.[J].2004,27(8).
- [15].Nonalcoholic steatohepatitis clinical research network.[J].2003,37(2).
- [16]Kuncewicz T,Yu ZY,Kone BC,etc.Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide.[J].2003,285(2).
- [17]Ortiz PA,Garvin JL.The role of reactive oxygen species in the regulation of tubular function.[J].2003,179(3).
- [18]S H, Caldwell,D H, Oelsner,J C, Iezzoni,etc.Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.[J].1999,29.
- [19]Daniela, Salvemini,Dennis P, Riley,Salvatore, Cuzzocrea.SOD mimetics are coming of age.[J].2002,1(5).
- [20]Taysi S,Savas MC,Yilmaz O,etc.Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis.[J].2004,34(1).
- [21]Kahn BB,Flier JS.Obesity and insulin resistance.[J].2000,106(4).
- [22]Sanyal AJ.Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.[J].2005,2(1).
- [23]Koteish A,Diehl AM.Animal models of steatosis.[J].2001,21(1).
- [24]Chitturi S,Farrell GC.Etiopathogenesis of nonalcoholic steatohepatitis.[J].2001,21(1).
- [25]Hashimoto T,Fujita T,Usuda N,etc.Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype.[J].1999,274(27).
- [26]Cao Q,Ren CL,Ponomarenko A,etc.Model of nonalcoholic steatohepatitis[J].2004,79(3).